Pharmaterials Acquired by Quotient Sciences

UK-based CRO moves further up the supply chain with CDMO buy.

Drug development services organization Quotient Sciences disclosed mid-November that it had acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, in the UK. The acquisition expands Quotient’s formulation and manufacturing services footprint in the region and supports the growth of the company’s Translational Pharmaceutics® platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.

According to Quotient, the company’s portfolio of services “spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply.” Pharmaterials, founded in 2000, is located in a 48,000-square foot facility which houses 13 GMP manufacturing suites and includes space for future expansion.

Quotient Sciences’ CEO Mark Egerton offered the company’s outlook: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.